Real-World Data Shows Different GLP-1 Agonists Have Unique Safety Profiles

GLP-1 Receptor Agonists (GLP-1 RAs) are a class of medications crucial for managing type 2 diabetes and obesity by mimicking a natural hormone that regulates blood sugar and appetite. While highly effective, concerns persist regarding their potential endocrine (affecting hormone systems, e.g., pancreatitis) and dermatologic (skin-related, e.g., rashes) side effects. This study addresses the knowledge gap by investigating whether specific GLP-1 RAs exhibit distinct real-world safety profiles for these adverse events.

Analysis revealed significant differences in adverse event rates among the various GLP-1 RAs studied. > Patients treated with liraglutide showed a 1.8-fold higher incidence of acute pancreatitis compared to semaglutide (p<0.001), while dulaglutide had a 1.2-fold higher risk than semaglutide (p=0.03). Conversely, semaglutide was associated with a 25% higher rate of injection site reactions than dulaglutide (p<0.01), indicating a differential dermatologic profile. The incidence of thyroid C-cell hyperplasia was numerically higher with liraglutide (0.08%) compared to semaglutide (0.05%) and dulaglutide (0.06%), though this difference did not reach statistical significance (p=0.12). Overall, semaglutide demonstrated a more favorable endocrine safety profile but a slightly less favorable dermatologic profile in specific areas compared to other agents.